Valuation: Simulations Plus, Inc.

Market Cap 369M 321M 298M 274M 517M 35.2B 525M 3.52B 1.38B 17.52B 1.38B 1.35B 58.75B P/E 2026 *
43.4x
P/E 2027 * 39.8x
Enterprise Value 369M 321M 298M 274M 517M 35.2B 525M 3.52B 1.38B 17.52B 1.38B 1.35B 58.75B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 4.27x
Free-Float
83.08%
Yield 2026 *
-
Yield 2027 * -
1 day-0.38%
1 week-0.60%
1 month-0.44%
3 months+28.65%
6 months+7.93%
1 week 18.22
Extreme 18.22
18.39
1 month 18.19
Extreme 18.19
18.47
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.9
Extreme 7.9
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Sell

Executive/Senior Manager

-1,000 0.0050%
1/7/26 Sell

Founder

-4,177 0.0207%
15/6/26 Fiscal year

Executive/Senior Manager

3,150 0.0156%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-0.60%+40.02%-63.39% 369M
+1.10%+9.42%-28.30%-0.22% 33.1B
+0.94%+1.50%-49.61%+135.80% 11.9B
-4.23%+0.53%-26.39%+58.48% 5.4B
-2.32%+4.60% - - 2.18B
-0.21%+4.48% - - 1.79B
-4.69%-13.73%+14.06%-43.99% 1.61B
+3.26%+2.03%-32.81% - 1.05B
-1.59%-0.91%+32.32%+100.00% 857M
+6.25%+12.97%-38.34%-51.10% 819M
Average -0.19%+1.52%-11.13%+19.37% 5.91B
Weighted average by Cap. +0.32%+5.69%-30.31%+34.67%

Financials

2026 *2027 *
Net sales 81.87M 71.17M 66.25M 60.82M 115M 7.82B 117M 781M 306M 3.89B 307M 301M 13.05B 86.26M 74.98M 69.79M 64.08M 121M 8.23B 123M 823M 323M 4.1B 324M 317M 13.75B
Net income 9.53M 8.29M 7.71M 7.08M 13.37M 910M 13.58M 90.93M 35.69M 453M 35.8M 35.02M 1.52B 10.18M 8.85M 8.24M 7.56M 14.28M 972M 14.5M 97.1M 38.11M 484M 38.24M 37.4M 1.62B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
31/07/26 USD 18.23 -0.38% 377,979
30/07/26 USD 18.30 -0.16% 215,369
29/07/26 USD 18.33 -.--% 346,154
28/07/26 USD 18.33 -.--% 158,846
27/07/26 USD 18.33 -0.05% 391,624
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.23USD
Average target price
17.25USD
Spread / Average Target
-5.38%

Quarterly revenue - Rate of surprise